Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 108 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate... February 12, 2025 New drug available for rare thyroid cancer on NHS in England October 1, 2021 OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced... November 29, 2021 Load more HOT NEWS News digest – HPV vaccine, 1 million breast screenings missed and... Cómo comenzar a hacer ejercicio en el hogar durante el tratamiento... EMA Recommends Extension of Therapeutic Indications for Daratumumab EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim
